



INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

Meeting Minutes

Date: Wednesday, January 15, 2020

Time: 10:00 AM – 12:00 PM

Location: Foege N130A

- Members Present:**
1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
 2. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
 3. Richard Grant, Washington National Primate Research Center
 4. Garry Hamilton (*Community Member*)
 5. Stephen Libby, Laboratory Medicine (*IBC Chair*)
 6. Scott Meschke, Environmental & Occupational Health Sciences
 7. Susan Parazzoli (*Community Member*)
 8. Jason Smith, Microbiology (*IBC Vice Chair*)
 9. Eric Stefansson, Environmental Health & Safety (*Biosafety Officer, Animal Containment Expert*)
 10. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:03 a.m. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **APPROVAL OF MINUTES:**
 - The IBC Chair sought a motion to approve the minutes from the December 18, 2019 meeting.
 - A member made a motion to approve the December 18, 2019 minutes. Another member seconded the motion.
 - The committee voted unanimously to approve the December 18, 2019 meeting minutes.
4. **OLD BUSINESS:**
 - At the August 2019 meeting, Dr. Zhang's BUA was approved pending a successful lab inspection pending. This is still pending.
 - At the September 2019 meeting, Dr. Wood's BUA was approved pending a successful lab inspection. This is still pending.
 - At the December 2019 meeting, Dr. Mougous's BUA was approved pending a successful lab inspection. This BUA has been sent out.
 - At the December 2019 meeting, Dr. Rea's BUA was approved pending clarification of plasmid constructs and lentiviral vector gene inserts being used. This BUA has been sent out.
 - At the December 2019 meeting, Dr. West's BUA was approved pending the removal of lentiviral vector work from the BUA letter. This BUA has been sent out.
5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
 - a. Biosafety Officer Report
 - Dr. Lukehart's BUA *Immunology of Syphilis* was renewed for use of non-pathogenic *E. coli*, *Treponema* strains, and human and non-human primate blood, tissue, body fluids, and cell lines in vitro and in rabbits.
 - Dr. Rabinovitch's BUA *Flow Cytometry Cost Center* was renewed to allow cells pre-approved by EH&S and the IBC for BSL-1 and BSL-2 containment practices in vitro at the Pathology Flow Cytometry Core Facility.
 - Dr. Kerr added in vitro use of *Klebsiella pneumonia* to the BUA *Plasmid Maintenance*.
 - Dr. Nickerson's BUA *Northwest Genomics Center* was renewed for use of human blood, tissue, body fluids, and cell lines in vitro.
 - Dr. Salipante added non-recombinant strains of *Leishmania* for in vitro use to the BUA *Next-generation sequencing for clinical translation*.
 - Dr. Hofstetter removed and added lab space for the BUA *Viral Neuronal Tracing in Rodents with Spinal Cord Injury*.
 - Dr. Xin added new non-oncogenic gene inserts and adenoviral vectors administered to mice in the BUA *Studies on prostate homeostasis and prostate-related disease*.

- Dr. Nghiem registered new mRNA constructs to the BUA *Merkel Cell Carcinoma Studies*.
- Dr. Wong removed use of the Gene and Cell Therapy Core from the BUA *An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors*.
- The IBC Chair sought a motion to approve this month's Biosafety Officer Report.
- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report.

6. DURC REPORT: The Dual Use Research of Concern Institutional Review Entity (DURC IRE) did not meet this month because there were no applications to review.

7. SECTION III-D AMENDMENTS

- a. Koelle, David, change, *Immune Response and Pathogenesis of Viral Infection***
- The IBC Primary Reviewer presented the Primary Review.
 - This change application includes work with mice using a 3rd generation lentiviral vector transduced murine cell line.
 - The lab was recently inspected so an inspection was not required for this change.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Koelle.
 - The Committee voted unanimously to approve the draft BUA for Dr. Koelle.

8. INDIVIDUAL PROJECT REVIEWS

- b. Ailion, Michael, renewal, *Dense-core vesicles***
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The overall aim of this project is to identify and characterize genes involved in the release of peptide hormones such as insulin. Work includes generation and work with transgenic *C. elegans* and *C. nouraguensis* and lentiviral transduction of mammalian cell lines.
 - A successful lab inspection is still required for this approval.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ailion pending a successful lab inspection.
 - The Committee voted unanimously to approve the draft BUA for Dr. Ailion pending a successful lab inspection.
- c. Grant, Richard, renewal, *Primate Diagnostic Services Laboratories***
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The goal of this project renewal is to provide diagnostic services and reagents for detection and characterization of infectious agents in non-human primates.
 - The greatest biohazard risk to laboratory personnel is the work with non-human primate blood or body fluids.

- The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Grant.
 - The Committee voted unanimously to approve the draft BUA for Dr. Grant.
- d. Kueh, Hao Yuan, change, *Single-cell analysis of immune cell fate decisions*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This lab is adding the use of *Listeria monocytogenes* in mice and mouse cells to study bacterial infection.
 - The lab was recently inspected, so no inspection was required for this change.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kueh.
 - The Committee voted unanimously to approve the draft BUA for Dr. Kueh.
- e. Lieber, Andre, renewal, *In vivo HSC gene therapy in NHPs*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This project tests the safety and efficacy of a specific in vivo hematopoietic stem/progenitor cell transduction approach in non-human primates for translational gene therapy purposes.
 - Work includes use of gutless adenoviral vectors in vitro and in non-human primates.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Lieber.
 - The Committee voted unanimously to approve the draft BUA for Dr. Lieber.
- f. Liu, Qinghang, renewal, *Liu Lab Research Program*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The overall research goal is to understand molecular mechanisms of cardiac cell death and heart failure.
 - Work includes use of adenoviral vectors (E1a deleted), >2/3 adenovirus genome, adeno-associated viral vectors (adenovirus free), and lentiviral vectors, third generation, non-HIV pseudotyped replication deficient in transgenic mice.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Liu.
 - The Committee voted unanimously to approve the draft BUA for Dr. Liu.
- g. Reh, Thomas, renewal, *Photoreceptor Survival Factors in Mouse Cell Cultures*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This lab uses human, non-human primate, and mouse cells to study retina development. Work includes use of adeno-associated viral vectors (adenovirus free) and lentiviral vectors, third generation, non-HIV pseudotyped replication deficient.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.

- The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Reh.
 - The Committee voted unanimously to approve the draft BUA for Dr. Reh.
- h. Schwartz, Michael, renewal, *Neuro-Endocrine Control of Energy Balance (Rat)*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This research focuses on the mechanisms whereby the brain regulates energy balance and glucose metabolism and whether dysfunction in these systems contributes to obesity and diabetes. Work includes use of viral vectors in rats.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Schwartz.
 - The Committee voted unanimously to approve the draft BUA for Dr. Schwartz.
- i. Schwartz, Michael, renewal, *Neuro-Endocrine Control of Energy Balance (Mice)*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This research focuses on the mechanisms whereby the brain regulates energy balance and glucose metabolism and whether dysfunction in these systems contributes to obesity and diabetes. Work includes use of viral vectors in mice.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Schwartz.
 - The Committee voted unanimously to approve the draft BUA for Dr. Schwartz.
- j. Sniadecki, Nathan, new, *Cell therapy in mice*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This lab examines the use of human pluripotent stem cells and derivatives that have been transduced with adeno-associated viral vectors associated in myocardial repair.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Sniadecki.
 - The Committee voted unanimously to approve the draft BUA for Dr. Sniadecki.
- k. Thaler, Joshua, renewal, *Glial Control of Energy Balance*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This lab studies the mechanisms whereby the brain regulates energy balance and glucose metabolism. They do this by studying specific genes in cell culture and in vivo in rodents that allow them to regulate energy and glucose homeostasis.
 - Work includes use of adeno-associated viral vectors (adenovirus-free) and lentiviral vectors, non-HIV pseudotyped, replication deficient, RCV tested.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.

- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Thaler.
 - The Committee voted unanimously to approve the draft BUA for Dr. Thaler.
- I. Woodrow, Kim, renewal, *Drug Delivery for Developing Microbicides and Mucosal Immunity*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The goal of this project is to develop new pre-exposure prophylactic microbicide and vaccine delivery systems for preventing sexually transmitted infections.
 - Work includes recombinant or synthetic DNA/RNA (non-viral)-enhanced gene delivery in mice.
 - The lab was inspected and no deficiencies were identified.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Woodrow.
 - The Committee voted unanimously to approve the draft BUA for Dr. Woodrow.

9. SUBCOMMITTEE REPORTS:

- m. Sherman, David, new, *MTB Disease and Drug Response*
- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
 - The focus of this work is to understand molecular pathogenesis of TB infection and response to antimicrobials. Work includes use of *Mycobacterium tuberculosis*, *bovis*, *smegmatis*, *abscessus*, and *avium*.
 - This is a preliminary approval to allow the PI to begin work at UW. A lab inspection and trainings are still required. Additional biohazardous work will be reviewed by the IBC prior to use. Animal work will not take place at UW. EH&S will review SOPs as they are developed by the lab.
 - The draft BUA letter was shown.
 - A member made a motion to approve the draft BUA letter for Dr. Sherman. Another member seconded the motion.
 - The Committee voted unanimously to approve the draft BUA for Dr. Sherman.

10. FOR YOUR INFORMATION:

- The EH&S 2019 Annual Report is now available on the EH&S website.
- EH&S and the Office of Research will be working together to develop proper shipping and transportation of biological samples reminders for PIs.

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS:

There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 11:15 A.M.